Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q2 2025 Earnings Presentation

32 slides from Day One Biopharmaceuticals's earnings presentation, Aug 5, 2025

  1. Slide 1: Targeted therapies for people of all ages

    Targeted therapies for people of all ages August 2025 Day One Biopharmaceuticals

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life-threatening diseases

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner Commercial-stage biopharmaceutical company Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible Focused on advancing first- or best-in-class medicines for childhood and adult diseases Wh

  5. Slide 5: Day One's Future Potential Value creation

    Day One’s Future Potential Value creation Continued revenue growth from OJEMDA globally Indication expansion in front-line pLGG with FIREFLY-2 Generate clinical POC data in DAY301 program Fund pipeline expansion Focused capital allocation, leveraging our efficient operating model to maintain strong

  6. Slide 6: Pipeline and recent & anticipated milestones

    Product Candidate Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3/ Registrational Approved Recent & Anticipated Milestones Tovorafenib3 Type II RAF Inhibitor OJEMDA brand name in U.S.1 Ex-U.S. Rights: BRAF-altered relapsed pLGG FDA accelerated approval April 2024 EMA regulatory submission Q1 20

  7. Slide 7: Relapsed or refractory BRAF-altered pLGG: OJEMDA

    Relapsed or refractory BRAF-altered pLGG OJEMDA Nora Living with pLGG

  8. Slide 8: A serious and life-threatening disease

    A serious and life-threatening disease *Incidence of BRAF alterations varies across pLGG subtypes. 1 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-1408. doi:10.1177/0883073809342005. 2 Penman CL et al. Front Oncol. 2015;5:54. 3 Cohen AR., N Engl J Med. 2020;386

  9. Slide 9: Tablet formulation and pediatric-friendly powder for oral suspension

    Available in tablet formulation and pediatric-friendly powder for oral suspension Overview U.S. prescribing information for OJEMDA Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF

  10. Slide 10: Data from pivotal Phase 2 FIREFLY-1 trial

    Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA, in the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tumors shrink or remain stable Efficacy Safety Generally well-tolerated the

  11. Slide 11: Addressable opportunity in pLGG

    1 US Census. 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. 3 Penman CL et al. Front Oncol. 2015;5:54. 4 Cohen AR., N Engl J Med. 2020;386(20):1922-1931. 5 Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934-2941. 6 Faulkner C, et al. J Neuropathol Exp Neurol. 2015;74(9):867-

  12. Slide 12: Commercial performance by the numbers

    Commercial performance by the numbers 1 Prescriptions are approximations based on data available as of June 30, 2025. 2 Second quarter 2024 reflects a partial quarter following OJEMDA receiving U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April

  13. Slide 13: One year in: OJEMDA delivering steady revenue growth

    1 Q3 2024 and Q4 2024 revenue included approximately $1.6M and $1.4M, respectively of revenue associated with Ex-US sales which has been removed for the purposes of calculating compounded quarterly revenue growth rate. 2 Compounded quarterly growth represents the comparison of Q3 2024 to Q2 2025. Ne

  14. Slide 14: One year in: Consistent uptake driving quarterly OJEMDA growth

    Prescriptions For The Most Recent 12 Months OJEMDA Prescriptions (TRx)1 +15% One year in: Consistent uptake driving quarterly OJEMDA growth Achieved greater than 1,000 scripts in Q2 2025 Prescription Highlights Strong and consistent patient demand, driven by new patient starts and high percentage of

  15. Slide 15: Expanding prescriber adoption with meaningful growth opportunity remaining

    Expanding Prescriber Adoption with Meaningful Growth Opportunity Remaining Launch Dec 2024 Jun 2025 1 Patient 2-3 Patients 4-5 Patients Growing Depth of Prescribing by Account Since Launch 6+ Patients Continued growth in breadth of unique prescribers initiating at least one patient on OJEMDA Growth

  16. Slide 16: OJEMDA priorities to drive revenue growth in 2025

    OJEMDA priorities to drive revenue growth in 2025 r/r, relapsed or refractory. Drive depth of prescribing with current prescribers Encourage non-user HCPs to try OJEMDA in their next r/r pLGG patient Establish OJEMDA as standard of care in 2nd line r/r BRAF-altered pLGG Support prescribers and patie

  17. Slide 17: Pivotal Phase 3 trial of tovorafenib in front-line pLGG: FIREFLY-2

    Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2 Bradon Living with pLGG since age 11

  18. Slide 18: FIREFLY-2 trial design and endpoints

    Trial design Endpoints Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib vs SoC chemotherapy Eligibility: Patients aged up to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy Tovorafenib available as tablets and pediatric-friendly liqu

  19. Slide 19: DAY301: PTK7-targeted antibody-drug conjugate

    PTK7-targeted antibody-drug conjugate (ADC) DAY301

  20. Slide 20: Substantial development and commercial potential for DAY301

    Substantial development and commercial potential for DAY301 Novel ADC active in preclinical models, designed to maximize therapeutic window PTK7: clinically-validated ADC target Anti-tumor activity of anti-PTK7 ADC demonstrated in Phase 1b trial of Pfizer / Abbvie’s cofetuzumab pelidotin1 DAY301: po

  21. Slide 21: Opportunity for a next-generation PTK7 ADC with improved therapeutic index

    Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs Cofetuzumab pelidotin activity seen in multiple tumor types: Ovarian (Pt-resistant): ORR 27% (n=63) TNBC: ORR 21% (n=2

  22. Slide 22: DAY301 designed to maximize therapeutic index

    DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs Tumor regression at tolerable doses seen in multiple preclinical models Higher HNSTD in cyno toxicology studies; payload with known safety profile High cell permeability / bystander effect; low efflux (

  23. Slide 23: Improved tumor regression for DAY301 vs benchmarks in preclinical models

    Improved tumor regression activity demonstrated for DAY301 vs. benchmarks in multiple preclinical models DAY301: First-in-class potential PDX LD1-200615 HNSCC H-score 120 Vehicle Control antibody + DAY301 payload Control antibody + auristatin payload Cofetuzumab pelidotin, 5 mg/kg DAY301, 10 mg/kg *

  24. Slide 24: PTK7 expression and patient populations by indication

    Indication PTK7 Expression (>1+) U.S. Patient Population Cases/Deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC​ 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6-14 months15 Head & Neck SCC 75%1 54,540/11,5803 32%5 7.8 mon

  25. Slide 25: DAY301 Phase 1 clinical development plan

    Phase 1a: Monotherapy Dose Escalation FDA-cleared starting dose DL5 RD1 RD2 Identify two recommended dose levels for further evaluation, based on safety and anti-tumor activity BOIN design for efficiency of dose escalation Backfill active dose levels to generate additional safety data Enroll tumor t

  26. Slide 26: Summary

    Summary

  27. Slide 27: Second quarter 2025 financial results

    Second quarter 2025 financial results All financial information as of 6/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.6 million and $7.8 million for the three and six months ended 6/30/25, and $4.7 million and $9.4 million for the three and six months ended 6/30/24. 2 Include

  28. Slide 28: Day One is well positioned for sustainable growth and long-term success

    Inserted messaging but need help with formatting. Day One is well positioned for sustainable growth and long-term success Drive OJEMDA revenue growth Execute on clinical development pipeline for FIREFLY-2 and DAY301 Leverage our development and commercialization expertise to further expand our multi

  29. Slide 29: Appendix

    Appendix

  30. Slide 30: Tovorafenib: oral, selective, CNS-penetrant type II RAF inhibitor

    Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and pediatric-friendly liquid suspension Once weekly dosing Curren

  31. Slide 31: Overall response rate in evaluable patients

    51% Overall response rate (RAPNO-LGG) in 76 evaluable patients Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Range 76 64 12 45 31 39 39 39 (51) 33 (52) 6 (50) 22 (49) 17 (55) 13.8 5

  32. Slide 32: Warnings and precautions; OJEMDA safety data

    Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors No boxed warnings or contraindications TEAEs (≥ 30% of patients [n=137]) Preferred Term, n (%) Any Grade Grade ≥3 Any AE 137 (100) 86 (63)

Day One Biopharmaceuticals — Q2 2025 Earnings Presentation on 6ix